{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:15:21Z","timestamp":1789776921749,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jcpo.2023.100451","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T02:12:45Z","timestamp":1698804765000},"page":"100451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Starting and stopping cancer drugs: The need for randomized trials"],"prefix":"10.1016","volume":"38","author":[{"given":"David J.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcpo.2023.100451_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pharmthera.2012.08.001","article-title":"Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport","volume":"136","author":"Won","year":"2012","journal-title":"Pharm. Ther."},{"issue":"12","key":"10.1016\/j.jcpo.2023.100451_bib2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","article-title":"Drug interactions in oncology: how common are they","volume":"20","author":"Riechelmann","year":"2009","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jcpo.2023.100451_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102212","article-title":"A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma","volume":"24","author":"Bangi","year":"2021","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.jcpo.2023.100451_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"issue":"0","key":"10.1016\/j.jcpo.2023.100451_bib5","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"0","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.jcpo.2023.100451_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcpo.2023.100451_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2020009752","article-title":"Persistent challenges with treating multiple myeloma early","volume":"137","author":"Goodman","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jcpo.2023.100451_bib8","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2015-11-632745","article-title":"Is watch and wait still acceptable for patients with low-grade follicular lymphoma","volume":"127","author":"Armitage","year":"2016","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.jcpo.2023.100451_bib9","doi-asserted-by":"crossref","first-page":"12126","DOI":"10.1200\/JCO.2022.40.16_suppl.12126","article-title":"Delayed versus immediate start of chemotherapy in asymptomatic patients with metastatic cancer: A systematic review and meta-analysis","volume":"40","author":"Augustinus","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jcpo.2023.100451_bib10","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"3","key":"10.1016\/j.jcpo.2023.100451_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2023.100451_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/1097-0142(197607)38:1<388::AID-CNCR2820380156>3.0.CO;2-A","article-title":"The effect of measuring error on the results of therapeutic trials in advanced cancer","volume":"38","author":"Moertel","year":"1976","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jcpo.2023.100451_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.jcpo.2023.100451_bib14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1634\/theoncologist.2008-0075","article-title":"Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data","volume":"13","author":"Stein","year":"2008","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jcpo.2023.100451_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096316","article-title":"Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example","volume":"9","author":"Burotto","year":"2014","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.jcpo.2023.100451_bib16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial","volume":"2","author":"George","year":"2016","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.jcpo.2023.100451_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.1992.10.6.904","article-title":"Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial","volume":"10","author":"Nordic Gastrointestinal Tumor Adjuvant Therapy Group","year":"1992","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jcpo.2023.100451_bib18","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/sj.bjc.6602841","article-title":"A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer","volume":"93","author":"Ackland","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"9747","key":"10.1016\/j.jcpo.2023.100451_bib19","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcpo.2023.100451_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.jcpo.2023.100451_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D\u2019Arena","year":"2011","journal-title":"Leuk. Lymphoma"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538323000681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538323000681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:41:41Z","timestamp":1719315701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538323000681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":21,"alternative-id":["S2213538323000681"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2023.100451","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Starting and stopping cancer drugs: The need for randomized trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2023.100451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100451"}}